QNRX - Quoin Pharmaceuticals Ltd. Total Debt to Capital

The market valuation chart for Quoin Pharmaceuticals (QNRX) demonstrates a standalone debt-to-equity ratio of 0.00, while global conflicts are hindering international trials and reagent procurement. The business develops therapies for rare epidermal pathologies, mitigating risks through portfolio diversification. The firm is currently in a capital-raising phase, experiencing an operating deficit due to a lack of revenue-generating products.

Developing unique drugs for the treatment of rare dermatological pathologies requires significant investment, making the financial stability ratio (debt-to-equity) a key indicator of the balance between borrowed funds and the own assets of Quoin Pharmaceuticals (QNRX). Analyzing this ratio allows an investor to assess the company's degree of dependence on creditors and determine whether the debt load creates risks for the business's capitalization.